Sirius Red

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Mitsubishi Tanabe Pharma, CSE, Asthma, AGN, CKD, Fibrosis, Repirinast, B cell, Chronic kidney disease, Company, LTD, Disease, Acquisition, Immunoglobulin E, Telmisartan, Blood pressure, Patient, Mitsubishi, NASH, Sirius Red, CEO, CGMP, Pharmaceutical industry

Repirinast, in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis conducted by NASH, reduced fibrosis by 50% with statistical significance.

Key Points: 
  • Repirinast, in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis conducted by NASH, reduced fibrosis by 50% with statistical significance.
  • As part of the new CKD research program, the Company will also investigate the use of Repirinast in acute interstitial nephritis.
  • Research conducted in Australia would be reimbursed under the Australian Scientific Research Tax Credit Program at a rate of 43.5%.
  • He conducts an active patient-oriented research program investigating the translational and epidemiological aspects of acute kidney injury (AKI) and other kidney related disorders.